Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

26. května 2026 aktualizováno: National Institute of Allergy and Infectious Diseases (NIAID)

A Nonrandomized Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

This phase 1 study will evaluate the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are in overall good health. The study will enroll about 42 participants at multiple study sites. Researchers will assess whether these vaccines can start or strengthen antibody responses against HIV. The study will also evaluate how a closely monitored planned pause in antiretroviral therapy affects these immune responses.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

42

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Argentina
      • Buenos Aires, Argentina, C1427CEA
  • Peru
      • Lima, Peru, 15063
        • Barranco CRS (Site ID: 11301)
        • Kontakt:
          • Consuelo T. Ramirez
          • Telefonní číslo: 210 51-1-2067800
      • Lima, Peru, 15001
        • Via Libre CRS (Site ID: 31909)
        • Kontakt:
      • Lima, Peru, 15088
        • San Miguel CRS (Site ID: 11302)
        • Kontakt:
    • Provincia Constitucional del Callao
      • Bellavista, Provincia Constitucional del Callao, Peru, 07006
        • Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS (CITBM) - Unidad de Ensayos Clínicos (UNIDEC) (Site ID: 31970)
        • Kontakt:
          • Fanny G. Rosas Benancio
          • Telefonní číslo: 1007 51-1-4800401
          • E-mail: frosas@citbm.pe
  • Spojené státy
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35222
        • Alabama CRS (Site ID: 31788)
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30308
        • The Ponce de Leon Center CRS (Site ID: 5802)
        • Kontakt:
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Beth Israel Deaconess Medical Center / BIDMC VCRS (Site ID: 32077)
        • Kontakt:
    • Washington
      • Seattle, Washington, Spojené státy, 98109
        • Seattle Vaccine and Prevention CRS (Site ID: 30331)
        • Kontakt:

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Able and willing to provide informed consent.
  • Age 18 to 60 years.
  • Documented HIV infection.
  • Lowest (nadir) CD4+ count between 250 and 450 cells/mm³.
  • On stable combination antiretroviral therapy (ART) for at least 48 weeks prior to screening.
  • Plasma HIV RNA <50 copies/mL for at least 48 weeks prior to enrollment, allowing limited transient increases.
  • CD4+ count >450 cells/mm³ and CD4+ percentage ≥15%.
  • Willing and able to comply with study visits and procedures.
  • Agrees not to participate in another investigational study during participation unless approved.
  • In general good health, with no clinically significant findings on physical exam or laboratory testing.
  • Hemoglobin ≥11.0 g/dL (women) or ≥13.0 g/dL (men).
  • Absolute neutrophil count ≥750/mm³.
  • Platelet count ≥100,000/mm³.
  • ALT <2.5 × upper limit of normal.
  • Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m².
  • Serum creatinine ≤1.1 × upper limit of normal.
  • Serum calcium >8.5 mg/dL.
  • Blood pressure within acceptable limits.
  • Agrees to use condoms during the specified period when ART is interrupted until HIV RNA is undetectable.
  • No evidence of active hepatitis C infection.
  • No evidence of active hepatitis B infection.
  • For individuals of pregnancy potential: negative pregnancy test prior to enrollment and agreement to use effective contraception during the required study period.
  • Agreement not to seek pregnancy during the required study period.

Exclusion Criteria:

  • Current use of ART that includes non-nucleoside reverse transcriptase inhibitors (NNRTIs).
  • Use of long-acting ART within 3 months prior to enrollment.
  • Known resistance to any component of the current ART regimen (excluding M184V/I mutation).
  • Resistance to one or more drugs in two or more ART classes (excluding M184V/I mutation).
  • Initiation of ART during acute HIV infection (within 1 year of HIV acquisition, if known).
  • History of advanced HIV-related illness (CDC Category C), except recurrent pneumonia, within 10 years prior to screening, or history of CD4 count <200 cells/mm³ within the past 10 years.
  • History of severe HIV-related conditions, including opportunistic infections, HIV-associated cancers, lymphoma, neurocognitive disease, or progressive multifocal leukoencephalopathy.
  • Active or recent non-HIV-related cancer requiring systemic treatment within 36 months or expected need for treatment within 12 months (excluding minor skin cancers).
  • Active hepatitis B or hepatitis C infection.
  • Significant liver disease, including cirrhosis or advanced fatty liver disease.
  • Untreated or incompletely treated active or latent tuberculosis.
  • Pregnancy or breastfeeding.
  • Body mass index (BMI) ≥40 kg/m², unless approved.
  • Diabetes mellitus, except well-controlled type 2 diabetes as allowed.
  • History of or current atherosclerotic cardiovascular disease, including heart attack, angina, stroke, or peripheral arterial disease.
  • Previous receipt of an investigational HIV vaccine (prior placebo recipients allowed).
  • Receipt of a non-HIV investigational vaccine within 1 year, unless approved or licensed.
  • Conditions causing impaired immune function or use of immunosuppressive medications within the specified timeframe.
  • Prior receipt of anti-HIV monoclonal antibody therapy.
  • Receipt of certain vaccines within restricted timeframes prior to enrollment (including live or mRNA vaccines within 4 weeks).
  • Receipt of other vaccines within 14 days prior to enrollment.
  • History of myocarditis or pericarditis.
  • Recent initiation of allergy immunotherapy within 1 year (unless stable or approved).
  • Recent use of investigational agents within restricted timeframes prior to enrollment.
  • History of severe allergic reaction to mRNA vaccines or polyethylene glycol-containing products.
  • History of angioedema.
  • Idiopathic urticaria within the past year.
  • Chronic urticaria or urticaria within the past year.
  • History of urticaria associated with vaccination.
  • Bleeding disorders or use of systemic anticoagulants.
  • Conditions associated with increased risk of clotting or bleeding.
  • History of seizures within the past 3 years or use of anti-seizure medications within that period.
  • Absence of spleen or impaired splenic function.
  • Active duty or reserve military personnel (U.S.).
  • Any clinically significant medical, psychiatric, or substance use condition that may affect safety or study participation.
  • Uncontrolled or severe asthma.
  • History of immune-mediated medical conditions, except limited stable or resolved conditions as allowed.
  • Allergy to local anesthetics (e.g., lidocaine).
  • Difficulty with venous access that would interfere with study procedures.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Základní věda
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Group 1

Participants will receive:

  • Week 0: DV700P-RNA
  • Week 8: DV700P-RNA
  • Week 16: DV701B1.1-RNA
Biologický: DV700P-RNA 100 mcg
Intramuscular injection
Biologický: DV701B1.1-RNA 100 mcg
Intramuscular injection
Experimentální: Group 2

Participants will receive:

  • Week 0: DV700P-RNA
  • Week 8: DV701B1.1-RNA
Biologický: DV700P-RNA 100 mcg
Intramuscular injection
Biologický: DV701B1.1-RNA 100 mcg
Intramuscular injection

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Local reactogenicity following study product administration
Časové okno: 14 days following each vaccination
Incidence and severity of solicited local reactogenicity signs and symptoms (injection site pain, erythema, and swelling), graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
14 days following each vaccination
Systemic reactogenicity following study product administration
Časové okno: 14 days following each vaccination
Incidence and severity of solicited systemic reactogenicity signs and symptoms (fever, fatigue, myalgia, arthralgia, headache, chills, nausea), graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
14 days following each vaccination
Number and description of serious adverse events (SAEs)
Časové okno: Through study completion, expected to be up to 88 weeks
Through study completion, expected to be up to 88 weeks
Number and description of medically attended adverse events (MAAEs)
Časové okno: Through study completion, expected to be up to 88 weeks
Through study completion, expected to be up to 88 weeks
Number and description of adverse events of special interest (AESIs)
Časové okno: Through study completion, expected to be up to 88 weeks
Through study completion, expected to be up to 88 weeks
Number and description of adverse events leading to study product discontinuation or participant withdrawal
Časové okno: Through study completion, expected to be up to 88 weeks
Through study completion, expected to be up to 88 weeks
Number and description of adverse events (AEs) following study product administration
Časové okno: 30 days following each vaccination
30 days following each vaccination
Response rate of differential serum neutralizing antibody responses to precursor detection viruses
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Proportion of participants with serum antibody responses demonstrating differential neutralization of precursor detection viruses and corresponding epitope knock-out mutant viruses, as measured by TZM-bl pseudovirus assay
At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of differential serum neutralizing antibody responses to precursor detection viruses
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of serum antibody neutralization of precursor detection viruses and corresponding epitope knock-out mutant viruses, as measured by TZM-bl pseudovirus assay
At Baseline (Week 0) and 2 weeks after last vaccination
Response rate of differential serum neutralizing antibody responses to precursor detection viruses after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Proportion of participants with serum antibody responses demonstrating differential neutralization of precursor detection viruses and corresponding epitope knock-out mutant viruses, as measured by TZM-bl pseudovirus assay
6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of differential serum neutralizing antibody responses to precursor detection viruses after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of serum antibody neutralization of precursor detection viruses and corresponding epitope knock-out mutant viruses, as measured by TZM-bl pseudovirus assay
6 weeks after last vaccination and 8 weeks after ART restart

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Frequency of Env-specific and V3-glycan-specific B cells
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Frequency of total Env-specific and V3-glycan-specific B cells, as assessed by flow cytometry
At Baseline (Week 0) and 2 weeks after last vaccination
Frequency of mutation of V3-glycan-specific B-cell receptor (BCR) sequences
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Frequency of mutation of V3-glycan-specific B-cell receptor (BCR) sequences, as assessed by B-cell sorting and BCR sequencing
At Baseline (Week 0) and 2 weeks after last vaccination
Frequency of Env-specific and V3-glycan-specific B cells after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Frequency of total Env-specific and V3-glycan-specific B cells, as assessed by flow cytometry
6 weeks after last vaccination and 8 weeks after ART restart
Frequency of mutation of V3-glycan-specific B-cell receptor (BCR) sequences after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Frequency of mutation of V3-glycan-specific B-cell receptor (BCR) sequences, as assessed by B-cell sorting and BCR sequencing
6 weeks after last vaccination and 8 weeks after ART restart
Response rate of serum IgG binding antibodies to autologous HIV Env stabilized trimers
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Proportion of participants with serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of serum IgG binding antibodies to autologous HIV Env stabilized trimers
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
At Baseline (Week 0) and 2 weeks after last vaccination
Epitope specificity of serum IgG binding antibodies to autologous HIV Env stabilized trimers
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Epitope specificity of serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
At Baseline (Week 0) and 2 weeks after last vaccination
Response rate of neutralization activity against heterologous tier 2 viruses
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Proportion of participants with neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of neutralization activity against heterologous tier 2 viruses
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Magnitude of neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
At Baseline (Week 0) and 2 weeks after last vaccination
Breadth of neutralization activity against heterologous tier 2 viruses
Časové okno: At Baseline (Week 0) and 2 weeks after last vaccination
Breadth of neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
At Baseline (Week 0) and 2 weeks after last vaccination
Response rate of serum IgG binding antibodies to autologous HIV Env stabilized trimers after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Proportion of participants with serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of serum IgG binding antibodies to autologous HIV Env stabilized trimers after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
6 weeks after last vaccination and 8 weeks after ART restart
Epitope specificity of serum IgG binding antibodies to autologous HIV Env stabilized trimers after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Epitope specificity of serum IgG binding antibody responses to autologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA)
6 weeks after last vaccination and 8 weeks after ART restart
Response rate of neutralization activity against heterologous tier 2 viruses after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Proportion of participants with neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of neutralization activity against heterologous tier 2 viruses after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Magnitude of neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
6 weeks after last vaccination and 8 weeks after ART restart
Breadth of neutralization activity against heterologous tier 2 viruses after last vaccination and after ART restart
Časové okno: 6 weeks after last vaccination and 8 weeks after ART restart
Breadth of neutralizing responses against heterologous tier 2 viruses, as measured by TZM-bl pseudovirus assay
6 weeks after last vaccination and 8 weeks after ART restart
Change in HIV Env sequence characteristics during ATI
Časové okno: During ATI
Comparison of HIV envelope (Env) sequence evolution during analytic treatment interruption (ATI) between participants who develop V3-glycan-specific antibodies and those who do not
During ATI
Change in HIV gag sequence characteristics during ATI
Časové okno: During ATI
Comparison of HIV gag sequence evolution during analytic treatment interruption (ATI) between participants who develop V3-glycan-specific antibodies and those who do not
During ATI

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

National Institute of Allergy and Infectious Diseases (NIAID)

Spolupracovníci

Duke University
Department of Health and Human Services (HHS)

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

2. června 2026

Primární dokončení (Odhadovaný)

31. srpna 2027

Dokončení studie (Odhadovaný)

31. srpna 2027

Termíny zápisu do studia

První předloženo

15. dubna 2026

První předloženo, které splnilo kritéria kontroly kvality

1. května 2026

První zveřejněno (Aktuální)

6. května 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

29. května 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

26. května 2026

Naposledy ověřeno

1. května 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • HVTN 808
  • 39218 (Jiný identifikátor: DAIDS Document ID)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na HIV

Klinické studie na DV700P-RNA 100 mcg

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Egypt

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit